The effect of mifepristone on breast cell proliferation in premenopausal women evaluated through fine needle aspiration cytology

Human Reproduction

Volumn 23, Issue 9, 2008, Pages 2072-2079

  Engman, M ^a   Skoog, L ^b   Soderqvist G ^a   Gemzell Danielsson, K ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Breast epithelium; Fine needle aspiration cytology; Mifepristone; Proliferation

Indexed keywords

ANDROSTENEDIONE; ESTRADIOL; HYDROCORTISONE; KI 67 ANTIGEN; MIFEPRISTONE; PLACEBO; PROGESTERONE; TESTOSTERONE; TRIOBE; UNCLASSIFIED DRUG; VITAMIN B COMPLEX;

ABDOMINAL DISEASE; ANDROSTENEDIONE BLOOD LEVEL; ARTICLE; ASPIRATION CYTOLOGY; BREAST CELL; BREAST EPITHELIUM; BREAST TENDERNESS; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ESTRADIOL BLOOD LEVEL; FEMALE; FEMALE FERTILITY; FLUSHING; HUMAN; HUMAN TISSUE; HYDROCORTISONE BLOOD LEVEL; IMMUNOCYTOCHEMISTRY; IN VIVO STUDY; LEIOMYOMA; PATIENT COMPLIANCE; PELVIC DISEASE; PREMENOPAUSE; PROGESTERONE BLOOD LEVEL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SWELLING; TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION; TREATMENT OUTCOME; URINARY EXCRETION; VAGINA BLEEDING;

EID: 54149115766     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/den228     Document Type: Article

References (30)

1. Baird DT, Brown A, Critchley HO, Williams AR, Lin S, Cheng L. Effect of long-term treatment with low-dose mifepristone on the endometrium. Hum Reprod 2003;18:61-68.
2. Bernardes JR Jr, Nonogaki S, Seixas MT, Rodrigues de Lima G, Baracat EC, Gebrim LH. Effect of a half dose of tamoxifen on proliferative activity in normal breast tissue. Int J Gynaecol Obstet 1999;67:33-38.
3. Brenner RM, Slayden OD, Nayak NR, Baird DT, Critchley HO. A role for the androgen receptor in the endometrial antiproliferative effects of progesterone antagonists. Steroids 2003;68:1033-1039.
4. Cameron ST, Glasier AF, Narvekar N, Gebbie A, Critchley HO, Baird DT. Effects of onapristone on postmenopausal endometrium. Steroids 2003;68:1053-1059.
5. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, Rodabough RJ, Gilligan MA, Cyr MG, Thomson CA et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003;289:3243-3253.
6. Cline JM, Soderqvist G, von Schoultz E, Skoog L, von Schoultz B. Effects of conjugated estrogens, medroxyprogesterone acetate, and tamoxifen on the mammary glands of macaques. Breast Cancer Res Treat 1998;48:221- 229.
7. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 1996;347:1713-1727.
8. Conner P, Soderqvist G, Skoog L, Graser T, Walter F, Tani E, Carlstrom K, von Schoultz B. Breast cell proliferation in postmenopausal women during HRT evaluated through fine needle aspiration cytology. Breast Cancer Res Treat 2003;78:159-165.
9. de Souza Sales JF Jr, Cabello C, Alvarenga M, Torresan RZ, Duarte GM. Nonproliferative epithelial alteration and expression of estrogen receptor and Ki67 in the contralateral breast of women treated with tamoxifen for breast cancer. Breast 2007;16:197-203.
10. Eisinger SH, Meldrum S, Fiscella K, le Roux HD, Guzick DS. Low-dose mifepristone for uterine leiomyomata. Obstet Gynecol 2003;101:243- 250.
11. Gaddy VT, Barrett JT, Delk JN, Kallab AM, Porter AG, Schoenlein PV. Mifepristone induces growth arrest, caspase activation, and apoptosis of estrogen receptor-expressing, antiestrogen-resistant breast cancer cells. Clin Cancer Res 2004;10:5215-5225.
12. Gemzell-Danielsson K, Swahn ML, Svalander P, Bygdeman M. Early luteal phase treatment with mifepristone (RU 486) for fertility regulation. Hum Reprod 1993;8:870-873.
13. Gemzell-Danielsson K, van Heusden AM, Killick SR, Croxatto HB, Bouchard P, Cameron S, Bygdeman M. Improving cycle control in progestogen-only contraceptive pill users by intermittent treatment with a new anti-progestogen. Hum Reprod 2002;17:2588-2593.
14. Gerdes J, Li L, Schlueter C, Duchrow M, Whienberg C, Gerlach C, Stahmer I, Kloth S, Brandt E, Flad HD. Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol 1991;138:867- 873.
15. Grow DR, Williams RF, Hsiu JG, Hodgen GD. Antiprogestin and/or gonadotropin-releasing hormone agonist for endometriosis treatment and bone maintenance: a 1-year primate study. J Clin Endocrinol Metab 1996;81:1933-1939.
16. Hofling M, Lundstrom E, Azavedo E, Svane G, Hirschberg AL, von Schoultz B. Testosterone addition during menopausal hormone therapy: effects on mammographic breast density. Climacteric 2007;10:155-163.
17. Isaksson E, von Schoultz E, Odlind V, Soderqvist G, Csemiczky G, Carlstrom K, Skoog L, von Schoultz B. Effects of oral contraceptives on breast epithelial proliferation. Breast Cancer Res Treat 2001;65:163-169.
18. Lakha F, Ho PC, Van der Spuy ZM, Dada K, Elton R, Glasier AF, Critchley HO, Williams AR, Baird DT. A novel estrogen-free oral contraceptive pill for women: multicentre, double-blind, randomized controlled trial of mifepristone and progestogen-only pill (levonorgestrel). Hum Reprod 2007;22:2428-2436.
19. Moguilewsky M, Philibert D. Biochemical profile of RU 486. In: Baulieu E-E, Segal SJ (ed). The Antiprogestin Steroid RU 486 and Human Fertility Control. New York: Plenum Press, 1985,87-97.
20. Preston-Martin S, Pike MC, Ross RK, Jones PA, Henderson BE. Increased cell division as a cause of human cancer. Cancer Res 1990;50:7415- 7421.
21. Santen RJ, Pinkerton J, McCartney C, Petroni GR. Risk of breast cancer with progestins in combination with estrogen as hormone replacement therapy. J Clin Endocrinol Metab 2001;86:16-23.
22. Skoog L, Humla S, Isaksson S, Tani E. Immunocytochemical analysis of receptors for estrogen and progesterone in fine-needle aspirates from human breast carcinomas. Diagn Cytopathol 1990;6:95-98.
23. Slayden OD, Brenner RM. Flutamide counteracts the antiproliferative effects of antiprogestins in the primate endometrium. J Clin Endocrinol Metab 2003;88:946-949.
24. Slayden OD, Nayak NR, Burton KA, Chwalisz K, Cameron ST, Critchley HO, Baird DT, Brenner RM. Progesterone antagonists increase androgen receptor expression in the rhesus macaque and human endometrium. J Clin Endocrinol Metab 2001;86:2668-2679.
25. Slayden OD, Zelinski MB, Chwalisz K, Hess-Stumpp H, Brenner RM. Chronic progesterone antagonist-estradiol therapy suppresses breakthrough bleeding and endometrial proliferation in a menopausal macaque model. Hum Reprod 2006;21:3081-3090.
26. Sodergard R, Backstrom T, Shanbhag V, Carstensen H. Calculation of free and bound fractions of testosterone and estradiol-17 beta to human plasma proteins at body temperature. J Steroid Biochem 1982;16:801-810.
27. Soderqvist G, Isaksson E, von Schoultz B, Carlstrom K, Tani E, Skoog L. Proliferation of breast epithelial cells in healthy women during the menstrual cycle. Am J Obstet Gynecol 1997;176:123-128.
28. Tseng L, Mazella J, Sun B. Modulation of aromatase activity in human endometrial stromal cells by steroids, tamoxifen and RU 486. Endocrinology 1986;118:1312-1318.
29. Walker KJ, Price-Thomas JM, Candlish W, Nicholson RI. Influence of the antioestrogen tamoxifen on normal breast tissue. Br J Cancer 1991;64:764-768.
30. Weiderpass E, Adami HO, Baron JA, Magnusson C, Bergstrom R, Lindgren A, Correia N, Persson I. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 1999;91:1131-1137.